Stryker reported strong first quarter 2025 results, with net sales rising 11.9% year over year to $5.87 billion, and organic net sales up 10.1%.

Growth was driven by a 13.4% increase in MedSurg and Neurotechnology and 9.7% growth in Orthopaedics. Reported operating income declined 13.9% to $837 million due to increased selling, general, and administrative expenses. Reported EPS dropped 17.6% to $1.69, but adjusted EPS grew 13.6% to $2.84, reflecting continued margin expansion. Stryker raised its full-year 2025 organic net sales growth guidance to 8.5%–9.5% and maintained adjusted EPS guidance of $13.20–$13.45, inclusive of the dilutive impact from the Inari acquisition and approximately $200 million in expected tariffs.

Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2025 on Thursday, May 1, 2025. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s first quarter that ended March 31, 2025.

Stryker will host a webcast at 4:30 p.m. ET on Thursday, May 1, 2025, to discuss its first quarter 2025 results. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's website two hours after the live call ends.

Stryker Completes Sale of U.S. Spinal Implants Business to VB Spine

Stryker has finalized the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, which will operate under the newly established company VB Spine, LLC. The move aligns with Stryker’s strategy to sharpen its focus on high-growth areas and innovation opportunities.

While divesting the spinal implants segment, Stryker remains active in the spine market through its Interventional Spine, Neurotechnology, and Enabling Technologies divisions, as well as a strategic partnership with VB Spine. As part of the agreement, VB Spine gains exclusive rights to use Mako Spine and Copilot technologies with its implants during spine procedures.

The transition of certain international markets to VB Spine is pending legal and regulatory approvals. Stryker expressed gratitude to its Spine team and confidence in their future success under VB Spine.

Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company’s board at the 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025.

Manny brings more than 30 years of experience leading high-performing organizations and advising senior executives on large-scale corporate transformations. He currently serves as Chairman of Bain & Company, following his tenure as Worldwide Managing Partner and CEO from 2018 to 2024. In that role, he led Bain’s global strategy and operations across more than 50 offices, driving the firm’s transformation to strengthen digital capabilities, expand its focus on sustainability, and preserve its award-winning culture.

Stryker has completed its acquisition of Inari Medical for $80 per share, strengthening its presence in the peripheral vascular market. Inari specializes in venous thromboembolism (VTE) clot removal without thrombolytic drugs, complementing Stryker’s neurovascular business.

The deal was finalized following a cash tender offer that secured 81.69% of Inari’s outstanding shares. Inari is now a wholly owned subsidiary of Stryker, and its stock has been delisted from Nasdaq.

Stryker Corporation has completed its acquisition of Inari Medical, Inc. through a merger with its subsidiary, Eagle 1 Merger Sub, Inc. The transaction, valued at approximately $4.94 billion in cash, was finalized on February 19, 2025, under the previously announced merger agreement dated January 6, 2025. Following the merger, Inari became a wholly owned subsidiary of Stryker.

The acquisition was executed under Section 251(h) of the Delaware General Corporation Law, allowing for a streamlined process without requiring a stockholder vote. Stryker had previously disclosed the merger details in its Form 8-K filed on January 7, 2025.

Stryker Corporation has completed its acquisition of Inari Medical through a cash tender offer of $80 per share, valuing the transaction at approximately $4.94 billion. The offer expired on February 18, 2025, with 81.69% of Inari’s outstanding shares tendered. Following the completion of the tender offer, Stryker merged its subsidiary, Eagle 1 Merger Sub, Inc., into Inari, making Inari a wholly owned subsidiary.

At the time of the merger, all outstanding Inari shares were converted into the right to receive $80 per share. Inari’s outstanding stock options and restricted stock units were also converted into cash payments. Stryker financed the acquisition using a combination of available cash and debt financing.

As part of the acquisition, Inari’s board of directors resigned, and Stryker-appointed directors took over. Inari’s bylaws and certificate of incorporation were amended. Inari’s stock was delisted from Nasdaq, and the company intends to terminate its SEC registration. Executive employment agreements for key Inari executives were modified to extend severance eligibility from 12 months to 24 months in the event of a qualifying termination.

Stryker Corporation announced that Glenn S. Boehnlein, the company's Vice President and Chief Financial Officer, will retire effective April 1, 2025. He will remain with the company as an Advisor to the CEO until March 31, 2026, receiving an annual base salary of $800,000 and eligibility for incentive bonuses.

Preston W. Wells, currently Vice President, Group Chief Financial Officer for Orthopaedics, has been appointed as the new Chief Financial Officer, effective April 1, 2025. Wells, who has been with Stryker since 2015, previously held leadership roles in investor relations, financial planning, and analysis. His new compensation package includes an annual base salary of $725,000, an 85% target bonus, and a long-term incentive award valued at $3 million.